Aromatic L-amino acid decarboxylase deficiency: Clinical features, treatment, and prognosis

Neurology

Volumn 62, Issue 7, 2004, Pages 1058-1065

  Pons, R ^a,d   Ford, B ^a   Chiriboga, C A ^a   Clayton, P T ^b   Hinton, V ^a   Hyland, K ^c   Sharma, R ^c   De Vivo, Darryl C ^a,e  

^a Coll Phys/Surgs Columbia Univ ^*  (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; ADRENERGIC RECEPTOR STIMULATING AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BROMOCRIPTINE; CATECHOLAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MELATONIN; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PHENELZINE; PYRIDOXINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE;

AROMATIC LEVO AMINO ACID DECARBOXYLASE DEFICIENCY; AUTONOMIC DYSFUNCTION; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CLINICAL FEATURE; DEVELOPMENTAL DISORDER; DYSKINESIA; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; HUMAN; HYPOKINESIA; INFANT; LONG TERM CARE; MALE; MUSCLE HYPOTONIA; MUTATION; OCULOGYRIC CRISIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 1842580680     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.62.7.1058     Document Type: Review

References (20)

1. Hyland K. Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. Semin Perinatol 1999;23: 194-203.
2. Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992; 42:1980-1988.
3. Korenke GC, Christen HJ, Hyland K, Hunneman DH, Hanefeld F. Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur J Pediatr Neurol 1997;1: 67-71.
4. Maller A, Hyland K, Milstien S, Biaggioni I, Butler IJ. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J Child Neurol 1997;12:349-354.
5. Abeling NG, van Gennip AH, Barth PG, van Cruchten A, Westra M, Wijburg FA. Aromatic L-amino acid decarboxylase deficiency: a new case with a mild clinical presentation and unexpected laboratory findings. J Inherit Metab Dis 1998;21:240-242.
6. Swoboda KJ, Hyland K, Goldstein DS, et al. Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology 1999;53:1205-1211.
7. Fiumara A, Brautigam C, Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies. Neuropediatrics 2002; 33:203-208.
8. Brautigam C, Wevers RA, Hyland K, Sharma RK, Knust A, Hoffman GF. The influence of L-dopa on methylation capacity in aromatic L-amino acid decarboxylase deficiency: biochemical findings in two patients. J Inherit Metab Dis 2000;23:321-324.
9. Burlina AB, Burlina AP, Hyland K, Bonafe L, Blau N. Autistic syndrome and aromatic L-amino acid decarboxylase deficiency. J Inherit Metab Dis 2001;24(suppl 1):34.
10. Sequeira S, Calado E, Wevers R. Aromatic L-amino acid decarboxylase deficiency. J Inherit Metab Dis 2001;24(suppl 1):34.
11. Chang YT, Mues G, McPherson JD, Bedell J, Marsh JL, Hyland K. Mutations in the human aromatic L-amino acid decarboxylase gene. J Inherit Metab Dis 1998;21(suppl 2):4.
12. Hyland K, Chang YT, Arnold LA, Brautigam C, Sharma RK, Hoffman G. Aromatic L-amino acid decarboxylase deficiency responsive to levodopa: identification of an active site glycine in exon three. J Inherit Metab Dis 1998;21(suppl 2):4.
13. Leigh RJ, Foley JM, Remler BF, Civil RH. Oculogyric crisis: a syndrome of thought disorder and ocular deviation. Ann Neurol 1987;22: 13-17.
14. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
15. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 2000;22(suppl 1):S65-80.
16. Voog L, Eriksson T. Is rat brain content of large neutral amino acids (LNAAs) a reflection of plasma LNAA concentrations? J Neural Transm Gen Sect 1992;87:133-143.
17. Lin MT. Effects of brain monoamine depletions on thermoregulation in rabbits. Am J Physiol 1980;238:R364-71.
18. Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther 1995;66:339-368.
19. Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH. New evidence for neurotransmitter influences on brain development. Trends Neurosci 1997;20:269-274.
20. Reisert I, Pilgrim C. Sexual differentiation of monoaminergic neuronsgenetic or epigenetic? Trends Neurosci 1991;14:468-473.